Primary mitral regurgitation (MR) is a pathology that alters mechanical loading on the left ventricle and induces a distinctive ventricular remodeling response known as eccentric hypertrophy. Drug therapies may alleviate symptoms, but only mitral valve repair can provide significant recovery of cardiac function and dimensions. However, 20% of patients still develop systolic dysfunction post-operatively despite being treated according to the current guidelines. Thus, better understanding of the hypertrophic process in the setting of ventricular volume overload (VO) is needed to improve and better personalize the management of MR. To address this knowledge gap, we employ a Bayesian approach to combine data from 70 studies on experimental volume overload in dogs and rats and use it to calibrate a logic-based network model of hypertrophic signaling in myocytes. The calibrated model suggests that growth in experimental VO is mostly driven by the neurohormonal response, with an initial increase in myocardial tissue stretch being compensated by subsequent remodeling fairly early in the time course of VO. This observation contrasts with a common perception that volume-overload hypertrophy is driven primarily by increased myocyte strain. The model suggests that Endothelin1 receptor activity plays a central role in driving hypertrophic responses and the activation of the fetal gene program. The model reproduces a number of responses to drug therapy not used in its calibration, and predicts that a combination of endothelin receptor antagonist and angiotensin receptor blockers would have the greatest potential to dampen cardiomyocyte hypertrophy and dysfunction in VO. Author Summary Mitral valve regurgitation is a common heart disease in which a malfunctioning valve allows part of the blood pumped by the heart to flow in the wrong direction. This condition overloads the heart by making it pump more blood volume than normal; the heart temporarily adapts by growing in mass and volume, but if untreated the condition can ultimately lead to heart failure and death. The most effective treatment is to surgically repair the valve; however, in many patients heart function deteriorates even after a successful surgery. Many researchers have studied this condition by experimentally overloading the hearts of dogs and rats, producing large amounts of data on the resulting geometric, mechanical, and biologic changes. Yet there is no clear answer on how to prevent the progression of the disease. In this work we integrate experimental data reported from 70 research articles on experimental volume overload through a simple model of heart mechanics and a more complex model of the molecular signaling pathways inside heart cells. We use a statistical approach to calibrate the computational model, so that it can predict not only average responses but also the degree of expected uncertainty for each prediction. We then use the model to explore how the heart responds to potential treatments during overload.
No takes yet. Share an insight, caveat, or question.
Bracamonte et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: